HLA Profile in Iraqi Rheumatic Valvulitis Patients

Background: Human leukocyte antigen (HLA) is the most polymorphic genetic system in man. The genes of this region influence susceptibility to certain disease. Objectives: This study was established to shed light on the possible association of HLA class I and II antigens with RV patients. Patients and Methods: Lymphocytotoxicity assay for HLA for class I and II typing had been done for (100) Iraqi patients suffering from rheumatic valvulitis (RV), the control groups consisting of (75 healthy individuals and 35 non rheumatic heart disease (NRHD) patients ). Results: The results showed a significant association of A33-Ags with these patients as compared with healthy and cardiac controls (P=0.005), (P=0.033) respectively. Another interesting finding was the low frequency of A1 in RV patients when compared with healthy control (p=0.002), suggesting that A1 allele may confer protective effect against this disease. In addition significant association between blood group B and RV was evident (p=0.04). An interesting observation was a strong association of blood group B and A33 among those patients (P<0.001). Conclusion: The present results are consistent with hypothesis that susceptibility to RV is genetically linked and in turn may be associated mainly with A33 in Iraqi patients

Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached$8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total,$40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this,$13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and$1.4 billion was repurposed from existing health projects. $3.1 billion (22.4$2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7$1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results demonstrate widespread moderate improvements in overall anemia prevalence but identify only three LMICs with a high probability of achieving the WHO GNT by 2030 at a national scale, and no LMIC is expected to achieve the target in all their subnational administrative units. Our maps show where large within-country disparities occur, as well as areas likely to fall short of the WHO GNT, offering precision public health tools so that adequate resource allocation and subsequent interventions can be targeted to the most vulnerable populations.Peer reviewe

Search for leptophobic Z ' bosons decaying into four-lepton final states in proton-proton collisions at root s=8 TeV

Peer reviewe

Search for high-mass diphoton resonances in proton-proton collisions at 13 TeV and combination with 8 TeV search

Peer reviewe

Search for black holes and other new phenomena in high-multiplicity final states in proton-proton collisions at root s=13 TeV

Peer reviewe

Search for heavy resonances decaying into a vector boson and a Higgs boson in final states with charged leptons, neutrinos, and b quarks

Peer reviewe

Search for heavy gauge W ′ bosons in events with an energetic lepton and large missing transverse momentum at √s = 13 TeV

A search is presented for W′ bosons in events with an electron or muon and large missing transverse momentum, using proton–proton collision data at √s=13 TeV collected with the CMS detector in 2015 and corresponding to an integrated luminosity of 2.3 fb−1. No evidence of an excess of events relative to the standard model expectations is observed. For a W′ boson described by the sequential standard model, upper limits at 95% confidence level are set on the product of the production cross section and branching fraction and lower limits are established on the new boson mass. Masses below 4.1 TeV are excluded combining electron and muon decay channels, significantly improving upon the results obtained with the 8 TeV data. Exclusion limits at 95% confidence level on the product of the W′ production cross section and branching fraction are also derived in combination with the 8 TeV data. Finally, exclusion limits are set for the production of generic W′ bosons decaying into this final state using a model-independent approach